The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

208 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-19

Study Completion Date

2024-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures \[1\]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Lockdown During COVID 19 Pandemic on Liver Disease and Metabolic Parameters.

NCT05028842

Liver Diseases

COMPLETED

Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis

NCT01412593

End Stage Liver Disease

UNKNOWN PHASE1/PHASE2

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05357352

Non-Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis

COMPLETED

Trial of Faecal Microbiota Transplantation in Cirrhosis

NCT02862249

Cirrhosis of the Liver

COMPLETED PHASE3

COVID-19 in Patients With Chronic Liver Diseases

NCT04439084

COVID-19 Chronic Liver Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Frailty Sarcopenia COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC

This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.

Intervention Type BEHAVIORAL